The notion of using peripheral inflammation to personalize treatment in depression is supported by a recent randomized controlled trial with the tumor necrosis factor (TNF)-α antagonist, infliximab, providing some evidence that patients with high levels of inflammation are more likely to respond to an adjuvant treatment with antiinflammatory drugs (Raison et al., 2013). This evidence concerns the gene TNF and depressive symptom measurement.